{"id":380,"date":"2020-07-18T11:03:52","date_gmt":"2020-07-18T11:03:52","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=380"},"modified":"2020-07-18T11:03:52","modified_gmt":"2020-07-18T11:03:52","slug":"17-july-2020-darunavir-proportion-of-negative-pcr-results-at-day-7-was-46-7-in-the-drv-c-compared-to-60-in-control-groups","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/17-july-2020-darunavir-proportion-of-negative-pcr-results-at-day-7-was-46-7-in-the-drv-c-compared-to-60-in-control-groups\/","title":{"rendered":"(17 July 2020) Darunavir- proportion of negative PCR results at day 7 was 46.7% in the DRV\/c compared to 60% in control groups"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Antiviral Activity and Safety of Darunavir\/Cobicistat for the Treatment of COVID-19<\/p>\n<p>https:\/\/doi.org\/10.1093\/ofid\/ofaa241<\/p>\n<p class=\"\">In this single-center, randomized, and open-label trial, mild patients with&nbsp; COVID-19 were enrolled in Shanghai, China. Participants were randomized to receive DRV\/c for 5 days on the top of interferon alpha 2b inhaling or interferon alpha 2b inhaling alone. The primary end point was the virological clearance rate of oropharyngeal swabs at day 7 after randomization in the intention-to-treat population (clinicaltrials.gov: NCT04252274). The proportion of negative PCR results at day 7 was 46.7% (7\/15) and 60.0% (9\/15) in the DRV\/c and control groups (P = .72), respectively. The viral clearance rate at day 3 was 20% (3\/15) in both study groups, while the number increased to 26.7% (4\/15) in the DRV\/c group and remained 20% (3\/15) in the control group at day 5. Fourteen days after randomization, 1 participant in the DRV\/c group progressed to critical illness and discontinued DRV\/c, while all the patients in the control group were stable (P = 1.0). The frequencies of adverse events in the 2 groups were comparable. Five days of DRV\/c did not increase the proportion of negative conversion vs standard of care alone, although it was well tolerated.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Antiviral Activity and Safety of Darunavir\/Cobicistat for the Treatment of COVID-19 https:\/\/doi.org\/10.1093\/ofid\/ofaa241 In this single-center, randomized, and open-label trial, mild patients with&nbsp; COVID-19 were enrolled in Shanghai, China. Participants were randomized to receive DRV\/c for 5 days on the top&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/17-july-2020-darunavir-proportion-of-negative-pcr-results-at-day-7-was-46-7-in-the-drv-c-compared-to-60-in-control-groups\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(17 July 2020) Darunavir- proportion of negative PCR results at day 7 was 46.7% in the DRV\/c compared to 60% in control groups&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[6,23,4],"tags":[74],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/380"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=380"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/380\/revisions"}],"predecessor-version":[{"id":381,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/380\/revisions\/381"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=380"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=380"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=380"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}